Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
Author(s) -
Cristina Pascual,
María Eva MingotCastellano,
A Fuentes,
José García-Arroba Peinado,
Joan Cid,
Moraima Jiménez,
David Valcárcel,
Inés GómezSeguí,
Javier de la Rubia,
Paz Martin,
Rosa Goterris,
Luís Hernández,
Inmaculada Tallón,
Sara Varea,
Marta Fernández,
Nadia GarcíaMuñoz,
Míriam Vara,
Miguel Fernández Zarzoso,
Faustino GarcíaCandel,
María Liz Paciello,
Irene GarcíaGarcía,
Saioa Zalba,
Verónica Campuzano,
José María GarcíaGala,
Julia Vidán Estévez,
Gemma Moreno Jiménez,
José Luis López Lorenzo,
Elena González Arias,
Carmen Freiría,
Maria Solé-Bundó,
Laura Francisca Ávila Idrovo,
José Carlos Hernández Castellet,
Naylen Cruz,
Esperanza Lavilla,
Albert Pérez-Montaña,
Jon Ander Atucha,
María Esperanza Moreno Beltrán,
Juán Ramón Moreno Macías,
Ramón Salinas,
Julio del Río-Garma
Publication year - 2022
Publication title -
blood advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.685
H-Index - 39
eISSN - 2473-9537
pISSN - 2473-9529
DOI - 10.1182/bloodadvances.2022008028
Subject(s) - medicine , rituximab , gastroenterology , refractory (planetary science) , odds ratio , concomitant , physics , lymphoma , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom